Objective. The objective of this study was to evaluate if the anti-inflammatory properties of bisphosphonates and their effect on bone turnover could be useful in the treatment of AS.
Introduction
NSAIDs are recommended as the first-line drug treatment of AS, but gastrointestinal tolerability and increased cardiovascular risk prevent their chronic use [1] .
TNF-a blockers (infliximab, etanercept, adalimumab and golimumab) are effective in controlling inflammation and pain and improving functionality in AS [2] but are much more expensive than conventional treatments and are contraindicated in patients with tuberculosis, multiple sclerosis and malignancy. A crucial role in the progression of skeletal lesions in AS is played by local overactivity of osteoclastic bone resorption followed by excess bone formation [3] .
Bisphosphonates, in addition to their anti-osteoclastic effects, seem to be associated with anti-inflammatory activity [4] , and this provides a reasonable rational for a few uncontrolled clinical trials [47] .
Here we compare the 6-month effect of neridronate, an amino-bisphosphonate similar to pamidronate [8] , and infliximab in patients with AS.
Patients and methods

Study design
This was a 6-month open-label study on active AS carried out in a single centre. After a 4-week run-in period, patients were consecutively assigned in a 1:1 ratio to receive either neridronate or infliximab.
The study was approved by the research ethics board of the University of Verona and informed consent was obtained from all participating patients.
Patients
Patients met the modified New York diagnostic criteria for AS and had an active disease as defined by a BASDAI score 54 despite maximum recommended or tolerated doses of NSAIDs assumed in the 12-week run-in period.
Patients could have been receiving SSZ at a stable dosage for 3 months prior to study entry and the dosages were maintained constant during the study.
Exclusion criteria were any corticosteroid therapy within the 3 months prior to study entry, renal insufficiency (defined as a serum creatinine 52 mg/dl), severe infections or a history of tuberculosis, HBV, HCV, neuropathy or malignancy within the past 5 years.
Treatments
Neridronate (100 mg in 250 ml of saline solution) was infused monthly for 6 months. Infliximab was administered at a dosage of 5 mg/kg in 250 ml of saline solution over 2 h at week 0, 2 and 4 and then every 6 weeks for a total period of 6 months in an outpatient facility.
Efficacy assessment
The primary efficacy measure was the BASDAI. Secondary clinical efficacy measures included the following: BASFI, BASMI, ESR, CRP level, 10-cm visual analogue scale (VAS) of pain and BMD as measured by DXA at the lumbar spine (LS) and hip (Hologic Delphi, Hologic, Waltham, MA, USA).
Swollen joint counts, enthesitis and uveitis were recorded. Clinical assessments were done at screening (4-week run-in period), baseline, and at month 3 and 6.
All clinical assessments were performed by an external examiner blinded to the assigned treatment. If a patient withdrew from the study before the end of study, additional assessments, including ESR and CRP measurements, were performed at the time of withdrawal. LS total hip and femoral neck (FN) DXA was performed at baseline and at the final visit. The results were expressed as T scores and patients were classified as osteopenic for a T score between À1 and À2.5 and osteoporotic for a T score 4À2.5.
Statistical analysis
Statistical analysis was performed using SPSS 13 (SPSS, Chicago, IL, USA). The results were expressed as mean (S.D. or S.E.). Changes vs baseline were tested by analysis of variance (ANOVA) and then by paired t-test. The between-group differences were evaluated by one-way ANOVA and Bonferroni test for multiple comparisons and by chi-square for dichotomous variable (e.g. proportion of responders). Significance was set at a P < 0.05.
Results
A total of 68 patients were screened for eligibility in the study. Eight patients were excluded because their BASDAI scores were <4 after the 12-week run-in period while on treatment with full doses of NSAIDs. Thirty of the remaining patients were assigned to neridronate and 30 to infliximab. All patients completed the study. The characteristics, including dose and type of NSAID, of the two treatment groups at baseline were very similar (Table 1) . Two patients, one in the neridronate group and one in the infliximab group, were receiving SSZ. Six patients had psoriasis and one had IBD without peripheral arthritis. The proportion that was HLA-B27 positive was identical (95%).
The BASDAI score decreased by 1.54 (À30.7%, P < 0.05 vs baseline) and 1.43 (À29.5%, P < 0.05 vs baseline) at 3 months and by 1.72 (À35.6%, P < 0.05 vs baseline) and 1.62 (À32.0%, P < 0.05 vs baseline) at the end of 
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Bisphosphonates vs infliximab in AS study in the neridronate and infliximab groups, respectively. Differences between treatment arms were not significant at 3 months or at the final assessment (Table 2) . Changes in the BASFI were very similar ( Table 2) . The VAS for axial pain decreased by 1.9 cm at 3 months (P = 0.001 vs baseline) and by 2.2 cm by 6 months (P < 0.0001 vs baseline) in the neridronate group. In the infliximab group the VAS changes were 1.6 at 3 months (P = 0.03 vs baseline) and 2.2 at 6 months (P = 0.007 vs baseline). A non-significant (NS) difference between treatments was observed ( Table 2) .
The BASMI was not significantly modified in neridronate or infliximab groups (Table 2 ).
In the neridronate group, no variations in ESR and CRP were observed (Table 2) , while in patients given infliximab, both decreased significantly vs baseline and vs neridronate at all time points (Table 2) .
Changes in the BASDAI were not explained [analysis of covariance (ANCOVA)] by anthropometric, demographic, baseline ESR or CRP and clinical characteristics, neither in the entire cohort nor in the single group.
Absolute BMD values (mg/cm 2 ) and T scores at LS, FN and total hip were similar at baseline in the neridronate and infliximab groups. Osteoporosis was observed in 17.3%, 5.7% and 3.8% and osteopenia in 19.2%, 26.4% and 18.8% at LS, FN and total hip, respectively. No significant BMD variations were observed at 6 months in the infliximab group. In patients treated with neridronate, a significant increase was observed at the LS BMD (P < 0.05 vs baseline and vs infliximab) but not at the hip sites (Table 2) . Both treatments were well tolerated. Four patients reported a typical acute phase response [9] with transient arthralgia and myalgia after the first i.v. infusion of neridronate. Two of these patients also reported fever (37.8 and 38.5 C) for 2 days. In the infliximab group, two patients had a respiratory infection that required a delay in the scheduled infusion, and one patient had an infusion reaction (hypotension) treated with a single dose of steroids, which was also given immediately before the following infusions. 
Discussion
In this study we compared treatment with the TNF-a blocker infliximab and the bisphosphonate neridronate in patients with AS and found the clinical outcomes were very similar. Today TNF-a blockers are considered the second-line treatment for AS in patients unresponsive to NSAIDs [1, 2] . The widespread use of these agents is limited by their cost as well as their risk of infections and malignancies. The use of bisphosphonates in AS has been tested in a number of uncontrolled pilot studies [1, 4, 7] . The rationale for their use in AS is both their anti-inflammatory properties and the inhibition of bone turnover at the site of inflammation, where they accumulate in high concentrations.
The anti-inflammatory properties of bisphosphonates were suggested by a number of experimental and clinical studies, suggesting an effect on the monocyte/ macrophage lineage where they modulate the generation of several pro-inflammatory cytokines [4] . The effect of amino-bisphosphonates on the production of proinflammatory cytokines is typically associated with the acute phase reaction occurring mostly after the first infusion [9] , while chronic exposure is associated with a permanent decrease in circulating gd lymphocytes [10] .
Most studies with bisphosphonates in AS were carried out with pamidronate, with favourable results on symptoms [47] and a reduction of bone marrow oedema, as detected by fat-suppressed MRI, which is considered predictive of the development of syndesmophytes in affected joints [11] . In the only controlled study published so far, the effect of a single infusion of pamidronate 60 mg was compared with pamidronate 10 mg, considered as a control treatment. The 60 mg dosing was associated with a significantly larger reduction in BASDAI, BASFI and VAS pain scores [5] . The same authors in a later uncontrolled study showed that an intensive regime (60 mg at 1, 2, 14, 28 and 56 days) was effective in significantly improving disease activity after 84 days of follow-up [6] . The literature also includes a negative report in 21 patients given 60 mg pamidronate monthly over 6 months [12] .
We have shown that i.v. neridronate 100 mg given monthly for 6 months is as effective as infliximab in controlling the main symptoms of AS even though, as expected, ESR and CRP remained unchanged. This might suggest that a large proportion of the symptoms in AS are unrelated to the inflammatory process per se and more likely are related to increased bone turnover at the levels of the enthuses. This is the first long-term controlled trial on the efficacy of a bisphosphonate for the treatment of AS. The anti-resorptive potency of neridronate is very close to that of pamidronate: it has been estimated that 100 mg neridronate is equivalent to 90 mg pamidronate [8] . Thus the antiresorptive dose we used is somewhat higher than those hitherto tested with pamidronate. The treatment was well tolerated, with the only exception of the acute phase response occurring only after the first infusion and at a rate similar to that observed in patients given the same dose for other conditions [13] such as osteogenesis imperfecta [8, 14] , Paget's disease of the bone [13] and algodystrophic syndromes [15] .
Osteoporosis is commonly observed in AS. In our study $30% of the patients had osteopenia, while osteoporosis was observed in $20%. In patients treated with neridronate a significant increase in LS BMD was observed after 6 months of therapy, while no significant changes were seen on hip sites and in patients treated with infliximab. Even though we were unable to test its anti-fracture efficacy, these results should be considered when comparing the global clinical efficacy of the two treatments.
An open issue in the treatment of AS is the radiographic and functional progression of the disease. TNF-a blockers, including infliximab, appear to have little effect on the radiological progression of the disease [2] . It is likely that the bone metabolic changes characterized by initial bone resorption and then excess bone formation at inflammatory sites are related to residual inflammation that cannot be suppressed even by anti-TNF-a agents [3, 16, 17] .
Excess bone formation in AS has recently been attributed to overexpression of the Wnt signalling pathway [17, 18] . Interestingly we recently showed that neridronate treatment in osteoporotic patients is associated with increasing circulating sclerostin levels, resulting in a reduction in bone formation [19] . Together these observations might provide a rational for the combination of anti-TNF-a agents and bisphosphonates, considering the reasonable safety profile, at least over the first 5 years of treatment [20] , and the low cost of bisphosphonates.
Conclusion
In conclusion, in this study we have shown that high i.v. doses of the amino-bisphosphonate neridronate are effective in reducing symptoms of disease in AS patients. The effect at 6 months is similar to that obtained with standard infliximab therapy, with additional benefits on BMD changes. The main limitations of our study are its short duration together with the open-label treatment and the study size. Therefore further studies to confirm these results over a longer time frame are warranted, together with the possibility to explore the long-term efficacy and safety of combining bisphosphonates and anti-TNF-a therapy.
Rheumatology key messages
. Bisphosphonates decrease subchondral bone turnover and have anti-inflammatory properties. . Short-term treatment with neridronate or infliximab is equally effective in AS. . Bisphosphonates alone or in combination with anti-TNF might be considered for long-term AS therapy.
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